Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abenza Upgrades Research & Development Capabilities in Cambridge | Contract Pharma

What are you searching for?

Sign in
Breaking News

Abenza Upgrades Research & Development Capabilities in Cambridge

Invests in B cell discovery technologies and appoints Jamie Campbell as Vice President of Research & Development.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Abzena, a CDMO providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), is upgrading its research and development capabilities in Cambridge, including an investment in B cell discovery technologies and the appointment of Jamie Campbell as Vice President of Research & Development.

Investment in Primary B Cell Discovery Technologies

As part of its investment in primary B cell antibody discovery technologies, Abzena has implemented the Berkley Lights’ Beacon system, a cutting-edge platform that supports rapid antibody discovery, by isolating single B cells from a target-primed cohort of lymphocytes.
 
This technology further enhances the capabilities of Abzena’s R&D team in antibody discovery, enabling delivery of a diverse, better characterized panel of recombinant antibodies, in a significantly shorter time.  This platform strengthens Abzena’s existing capabilities in developability, bioconjugation, cell line development and manufacturing.

Appointment of Jamie Campbell as VP of R&D

Brought in to head up the Cambridge site and R&D team, Jamie Campbell has been appointed as Vice President of Research & Development.
 
Campbell brings 17 years of antibody discovery and development experience to the role and is responsible for building on the reputation of Abzena for meeting and exceeding client expectations. He will oversee the performance of Abzena’s target to lead business covering discovery, design & developability programs ensuring the continued improvement of our services and development of our R&D team. 
 
Campbell Bunce, chief scientific officer at Abzena said: “The introduction of B cell discovery to Abzena’s capabilities is a significant new advancement to our antibody offering and is part of a number of new developments in the pipeline for Abzena. Appointing Jamie to our team has further strengthened our skills and expertise within R&D, as he brings a wealth of experience to augment and build on our capabilities and the service we deliver for clients”.
 
As part of its new developments, Abzena is also working on its high throughput small scale production capabilities. This will support B cell antibody discovery by facilitating testing for affinity, stability, and mechanism of action early in the assay cascade. Abzena’s clients will then have access to an enhanced dataset across multiple parameters, without compromising on throughput or number of hits tested.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics